But until now drug companies had largely ignored Ebola, because there appeared to be little profit in developing a drug for populations that could not afford to pay for it.
Mais jusqu’ici les sociétés pharmaceutiques ont largement ignoré Ebola, car les bénéfices attendus semblent bien minces pour la mise au point d’un médicament destiné à des populations qui n’ont pas les moyens de se le payer.